Aurealis Therapeutics, a Swiss-Finnish private biopharmaceutical company, is now entering the clinical trial phase with its patented three-in-one combination product AUP-16 for chronic non-healing wounds and other regenerative diseases. The genetically modified lactic acid bacteria based therapy is designed to improve the quality of life for patients who requires tissue generation for example with diabetic foot ulcer. This is remarkable advancement for people who generally have only had access to medicines that treat symptoms versus promote tissue regeneration itself.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Internationally (various countries)
We exist to develop curative solutions that achieve total and faster healing for non-healing wounds and other complex inflammatory diseases with our four-in-one biologic drug, AUP-16.
Our goal is to create solid Phase 2 clinical efficacy data in diabetic foot ulcers and non-clinical proof-of-concept data in other inflammatory diseases by end of 2022, and to engage with strategic partners to ensure that this game changing technology benefits millions of patients.
Investors and Partnering
Chronic wounds, such as diabetic foot ulcers, venous leg ulcers and pressure ulcers, contribute major costs to healthcare systems and societies. Just in the United States, 8.2 million patients are impacted annually by non-healing wounds and related complications. The global market for chronic wound care is estimated at $10 billion, with a 5% annual growth rate, revealing a need for better treatment options than the ones currently available. The market is dominated by basic wound care products, advanced dressings, cellular and tissue based products, and medical devices. No approved drugs are marketed in USA and Europe, posing an untapped market for the first movers.
Aurealis Therapeutics is an innovative biotechnology company seeking to differentiate by offering a prescription drug with superior efficacy to these unmet medical indications and market. Our disruptive wound healing technology offers multiple benefits over conventional treatments and therapies, including:
- Combination therapy: four therapeutic components in one product
- Safe: extensively studied food-grade lactic acid bacteria
- Topical: therapeutic agents produced at the wound site
- Scalable: low-cost and scaled GMP production
Genetically modified lactic acid bacterial therapies are a game-changer for regenerative medicine that solves the problems of efficacy, safety, scale-up, cost and delivery of the therapeutic agents. Our first therapeutic product, AUP-16, has been extensively studied in pre-clinical settings, demonstrating its safety and effectiveness in wound healing.